$5.28
+0.15 (+2.92%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANNX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 1 with posted results
Held by 14 tracked-famous managers (Balyasny Asset Management L.P., Qube Research & Technologies Ltd, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, +9 more) · FINRA short interest 10.4 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)NCT07020819Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t)Open-label · Treatment | Phase 3 | Recruiting | Drug: Tanruprubart | Guillain-Barre Syndrome | 30 | 2026-12-31 | in 134 d | 2026-05-28 |
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)NCT06510816Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive VisitsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Vonaprument · Other: Sham Administration | Geographic Atrophy | 659 | 2026-10-31 | in 73 d | 2026-05-04 |
| Dose Study of ANX1502 in Healthy VolunteersNCT05521269Number of Participants with Treatment Emergent Adverse Events (TEAEs) After A Single Dose and Multiple Doses of ANX1502Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: ANX1502, Placebo | Healthy | 135 | 2024-11-19actual | — | 2024-12-27 |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeNCT04701164GBS Disability Score (GBS-DS) at Week 8Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ANX005, Placebo | Guillain-Barre Syndrome | 242 | 2024-04-20actual | — | 2025-05-29 |
| Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT04569435Number of Participants Who Experienced Treatment-Emergent Adverse EventsOpen-label · Treatment | Phase 2 | Completed | Drug: ANX005 | Amyotrophic Lateral Sclerosis | 17 | 2024-01-10actual | — | 2025-01-06 |
| A Study of ANX009 in Adult Participants With Lupus NephritisNCT05780515Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Biological: ANX009 | Lupus Nephritis | 7 | 2023-08-31actual | — | 2024-08-22 |
| Single Ascending Dose Study of ANX105NCT05288881Number of Participants Who Experienced Treatment-Emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: ANX105 · Drug: Placebo | Healthy | 23 | 2023-06-19actual | — | 2024-08-19 |
| A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyNCT04656561GA lesion growth rateRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ANX007 · Other: Sham comparator | Geographic Atrophy | 270 | 2023-03-28actual | — | 2024-08-21 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04691570results2026-06-30Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ANX005 | Warm Autoimmune Hemolytic Anemia (wAIHA) | 7 | 2023-01-17actual | — | 2026-06-30 |
| An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseNCT04514367Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's DiseaseOpen-label · Treatment | Phase 2 | Completed | Drug: ANX005 | Huntington Disease | 28 | 2022-01-28actual | — | 2023-01-31 |
| A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)NCT04535752Safety: Number of Participants Who Experienced Treatment-Emergent Adverse EventsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: ANX009, Placebo | Safety and Tolerability in Healthy Volunteers | 48 | 2021-06-26actual | — | 2021-08-30 |
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)NCT04035135Safety and tolerability of ANX005 when administered in combination with IVIg: incidence of TEAEs, SAEs, AE'sOpen-label · Treatment | Phase 1 | Completed | Drug: ANX005, Intravenous immunoglobulin | Guillain-Barré Syndrome | 14 | 2021-05-19actual | — | 2021-08-11 |
| Study of ANX007 in Participants With Primary Open-angle GlaucomaNCT04188015To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: 2.5mg ANX007, 5.0mg ANX007 · Other: Sham Procedure | Open Angle Glaucoma | 17 | 2019-06-03actual | — | 2020-08-20 |
| Single-dose Study of ANX007 in Participants With Primary Open-angle GlaucomaNCT03488550Safety and tolerability as measured by the occurrence of adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: ANX007 | Open-angle Glaucoma | 9 | 2018-08-03actual | — | 2020-08-20 |
| Single Dose Study of ANX005 in Healthy VolunteersNCT03010046Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03Randomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: ANX005 well tolerated at doses studied; study discontinued and initiated in patient population | Drug: ANX005, IVIg, Placebos | Safety and Tolerability in Healthy Volunteers | 27 | Jun 2018actual | — | 2020-08-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19